Health technology company Detect has introduced a new PCR-quality at-home Covid-19 rapid molecular test to meet the testing requirements at home, school, work and travel places in the US.
The Detect Covid-19 Test is a molecular rapid test, which integrates the sensitivity of a PCR lab test with the convenience and scalability of a typical rapid test.
The technology used by the test holds the potential to detect SARS-CoV-2 at lower viral loads than antigen tests, thereby helping in minimising pre-symptomatic spread with earlier detection.
Earlier this month, the company secured an emergency use authorisation (FDA) from the US Food and Drug Administration (FDA) for Detect Covid-19 Test.
It was approved only for the detection of nucleic acid from SARS-CoV-2 and not for any other viruses or pathogens.
Detect stated that it will prioritise Connecticut companies and schools as the company’s first customers to help keep the local community safe.
The company is selling the single Detect Covid-19 Test at a price of $49, and the reusable Detect Hub at a price of $39.
Detect’s Covid-19 test has recently been chosen by the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics Initiative (RADxSM) for a $8.1m contract to expand manufacturing.
The company’s technology is said to serve as a platform for future home tests such as influenza and sexually transmitted infections (STIs).
Detect is part of 4Catalyzer, a health technology accelerator that works to address challenging issues across life science research tools, medical devices and therapeutics.
